Red blood cell (RBC) transfusion is commonly prescribed in units and assessed through changes in recipient hemoglobin concentration. Unit count leaves the administered hemoglobin mass unspecified, while the concentration increment also reflects recipient blood volume, fluid balance, bleeding and cell persistence. This narrative review examines component hemoglobin content, quality specifications, preparation, storage and clinical studies of content-based allocation. Components meeting the same quality specifications can contain different hemoglobin masses [1]. Anticoagulants, additive solutions, container materials and processing further define the component administered. Hemolysis changes the distribution of hemoglobin between cellular and extracellular compartments; posttransfusion recovery measures subsequent cell persistence. Oxygen affinity and oxygen-release kinetics add functional information that concentration and mass alone do not capture. We propose prospective studies linking representative final-component measurements to delivered volume, recipient physiology and samples collected at defined times. The first test is whether measured administered hemoglobin mass improves prediction of the recipient increment beyond routine component and patient data. A subsequent comparison can assess the additional value of oxygen-release measurements and perfusion variables. Clinical benefit requires independently measured physiological and patient outcomes. This approach would make transfusion exposure more explicit and allow the value of individual component characterization to be tested within established compatibility and patient blood management practice.